Palladium Nanoparticles PdNPs applications in cancer treatment involving autophagy

Palladium Nanoparticles (PdNPs) and Autophagy

Palladium nanoparticles (PdNPs) have been studied for their potential in cancer treatment, particularly in relation to autophagy, a process where cells degrade and recycle their own components. Here are some key findings:

• Autophagy Induction: PdNPs can induce autophagy in cancer cells, which involves the formation of autophagosomes and the degradation of cellular components. This process can lead to cell death, making it a potential therapeutic target.

• Autophagic Flux Blockade: High concentrations of PdNPs can also block autophagic flux, which is the process of autophagosome formation and fusion with lysosomes. This blockade can impair the degradation capabilities of lysosomes and contribute to cell death.

• Synergistic Therapy: PdNPs can be used in combination therapies, such as with chemotherapy or photothermal therapy, to enhance the efficacy of cancer treatment. For example, copper-palladium alloy tetrapod nanoparticles (TNP-1) have been shown to work synergistically with autophagy inhibitors to treat drug-resistant cancers.

These findings suggest that PdNPs have potential applications in cancer treatment through mechanisms involving autophagy, but further research is needed to fully understand their therapeutic potential and safety.

References

• Palladium nanoparticles induce autophagy and autophagic flux blockade in Hela cells

• Phytoassisted synthesis and characterization of palladium nanoparticles (PdNPs); with enhanced antibacterial, antioxidant and hemolytic activities

• Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

• Green Chemistry Approach for Synthesis of Effective Anticancer Palladium Nanoparticles

• Palladium Nanoparticles as a Platform for Cancer Diagnosis and Treatment